

I

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,084,151 B2
APPLICATION NO. : 10/684227
DATED : August 1, 2006
INVENTOR(S) : Lin Zhi et al.

Page 2 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


wherein:

- R^1 is selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 heteroalkyl, COR^5 , CO_2R^5 , SO_2R^5 , and $CONR^5R^6$;
 R^2 and R^3 each independently is selected from the group of hydrogen, C_1 - C_6 alkyl, and C_1 - C_6 haloalkyl; or
 R^2 and R^3 taken together form a cycloalkyl ring of from three to twelve carbons;
 R^4 is selected from the group of hydrogen, F, Cl, Br, CN, OR^5 , C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, and C_1 - C_4 heteroalkyl;
 R^5 and R^6 each is independently selected from the group of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 heteroalkyl, and C_1 - C_4 haloalkyl;
 R^7 through R^9 each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2 , CN, OR^5 , NR^5R^6 , SR^5 , COR^5 , CO_2R^5 , $CONR^5R^6$, C_1 - C_8 alkyl, C_1 - C_8 heteroalkyl, C_1 - C_8 haloalkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl;
 R^{10} through R^{15} each independently is selected from the group of hydrogen, F, Cl, Br, OR^5 , C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, and C_1 - C_4 heteroalkyl; or
 R^{12} and R^{14} taken together form a bond, when Y is $CR^{14}R^{15}$; or
 R^{10} and R^{14} taken together form a bond, when Z is $CR^{14}R^{15}$;
Y and Z each independently is selected from the group of O, S, NR^6 and $CR^{14}R^{15}$;
and n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Col. 18, line 1-56

2. A compound of the formula:



(I)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,084,151 B2
APPLICATION NO. : 10/684227
DATED : August 1, 2006
INVENTOR(S) : Lin Zhi et al.

Page 3 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R^1 is selected from the group of hydrogen, C_1-C_4 alkyl, COR^5 , CO_2R^5 , and SO_2R^5 ;
 R^2 and R^3 each independently is selected from the group of C_1-C_4 alkyl;
 R^4 is selected from the group of hydrogen, F, Cl, Br, C_1-C_4 alkyl, and C_1-C_4 haloalkyl;
 R^5 and R^6 each is independently selected from the group of hydrogen, and C_1-C_4 alkyl;
 R^7 through R^9 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^5 , C_1-C_8 alkyl, C_1-C_8 heteroalkyl, and C_1-C_8 haloalkyl;
 R^{10} through R^{15} each independently is selected from the group of hydrogen, F, Cl, OR^5 , C_1-C_4 alkyl, C_1-C_4 haloalkyl; or
 R^{12} and R^{14} taken together form a bond, when Y is $CR^{14}R^{15}$; or
 R^{10} and R^{14} taken together form a bond, when Z is $CR^{14}R^{15}$;
Y and Z each independently is selected from the group of S, and $CR^{14}R^{15}$; and
n is 0, 1, or 2;

or a pharmaceutically acceptable salt thereof.

Col. 18-19 line 56-14

4. A compound according to claim 1, wherein said compound is selected from the group of:

9-Fluoro-5-(1,3-dithia-2-cyclohexylidene)-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 10);
8-methoxy-5-(1,3-dithia-2-cyclohexylidene)-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 13);
7,9-difluoro-5-(1,3-dithia-2-cyclohexylidene)-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 15);
7-fluoro-5-(1,3-dithia-2-cyclohexylidene)-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 17);
7-fluoro-5-cyclohexylidene-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 19);
7,9-difluoro-5-cyclohexylidene-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 20);
7-fluoro-5-(1,3-dithia-2-cyclohexylidene)-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 21); and
7-fluoro-5-(2-cyclohexenylidene)-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 23).

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 7,084,151 B2
APPLICATION NO. : 10/684227
DATED : August 1, 2006
INVENTOR(S) : Lin Zhi et al.

Page 4 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 19 Line 43-64

6. A compound of the formula:



(II)

wherein:

R^2 and R^3 are CH_3 ;

R^4 is selected from the group of F, Cl, Br, CH_3 , and CF_3 ;

R^5 is selected from the group of hydrogen, $\text{C}_1\text{--C}_4$ alkyl, $\text{C}_1\text{--C}_4$ heteroalkyl, and $\text{C}_1\text{--C}_4$ haloalkyl;

R^7 is hydrogen or F;


R^9 is selected from the group of hydrogen, F, Cl, Br, CN, OCH_3 , CH_3 , and CF_3 ;

n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

Col. 20-21 line 49-19

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,084,151 B2
APPLICATION NO. : 10/684227
DATED : August 1, 2006
INVENTOR(S) : Lin Zhi et al.

Page 5 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R^1 is selected from the group of hydrogen, C_1-C_4 alkyl, COR^5 , CO_2R^5 , and SO_2R^5 ;
 R^2 and R^3 each independently is selected from the group of C_1-C_4 alkyl;
 R^4 is selected from the group of hydrogen, F, Cl, Br, C_1-C_4 alkyl, and C_1-C_4 haloalkyl;
 R^5 and R^6 each is independently selected from the group of hydrogen, and C_1-C_4 alkyl;
 R^7 through R^9 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR^5 , C_1-C_8 alkyl, C_1-C_8 heteroalkyl, and C_1-C_8 haloalkyl;
 R^{10} through R^{15} each independently is selected from the group of hydrogen, F, Cl, OR^5 , C_1-C_4 alkyl, C_1-C_4 haloalkyl; or
 R^{12} and R^{14} taken together form a bond, when Y is $CR^{14}R^{15}$; or
 R^{10} and R^{14} taken together form a bond, when Z is $CR^{14}R^{15}$;
Y and Z each independently is selected from the group of S, and $CR^{14}R^{15}$; and
n is 0, 1, or 2;

or a pharmaceutically acceptable salt thereof.

Col. 20, Line 21-13

9. A pharmaceutical composition according to claim 8, wherein:

R^1 is hydrogen;
 R^2 and R^3 is CH_3 ;
 R^4 is selected from the group of F, Cl, Br, CH_3 and CF_3 ;
 R^7 is hydrogen or F;
 R^8 is selected from the group of H, CH_3 , OH, and OCH_3 ;
 R^9 is selected from the group of hydrogen, F, Cl, Br, CN, OCH_3 , CH_3 , and CF_3 ;
 R^{10} , R^{11} , R^{13} , R^{15} each independently is selected from the group of hydrogen, F, Cl, CH_3 , and CF_3 ; and

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,084,151 B2
APPLICATION NO. : 10/684227
DATED : August 1, 2006
INVENTOR(S) : Lin Zhi et al.


Page 6 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^{12} and R^{14} taken together form a bond, when Y is $CR^{14}R^{15}$.

Signed and Sealed this

Sixteenth Day of January, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looping initial "J" and a distinct "D".

JON W. DUDAS
Director of the United States Patent and Trademark Office